Aeolus Pharmaceuticl (AOLS) 0.2510 $AOLS
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Malignant Mesothelioma Therapeutics Pipeline Review 2014 - Analysis of 13 Companies & 22 Drug Profiles
M2 - Tue Apr 22, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db52sm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - MedImmune, LLC - Aduro BioTech, Inc. - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Advantagene, Inc. - Y's Therapeutics Co., Ltd. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - AEOL-10150 - Ad5-SGE-REIC/Dkk3 Gene Therapy - BAY-949343 - BERTA - BIW-8962 - BNC-105 - Bivalent Bispecific Tribody - CRS-207 - Drug For Mesothelioma - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - FPI-01 - LY-3023414 - Monovalent Trispecific Tribody - Oshadi D - Oshadi D Oshadi R - SentoClone - VS-4718 - YP-223 - YP-3 - YS-110 - YYP-218 - tremelimumab For more information visit http://www.researchandmarkets.com/research/db52sm/malignant
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
Marketwire - Fri Feb 14, 4:30PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2013.
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
Marketwire - Thu Feb 13, 6:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
Marketwire - Mon Feb 10, 6:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure
M2 - Fri Jan 24, 5:42AM CST
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) revealed on Thursday the receipt of notice for AEOL 10150 for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
Marketwire - Thu Jan 23, 9:53AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
Aeolus Announces Fiscal Year 2013 Financial Results
Marketwire - Mon Dec 23, 7:00AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months and twelve months ended September 30, 2013.
Aeolus Pharmaceuticals Inc submits application for new patent for AEOL 10150 for use in radiation exposure
M2 - Fri Dec 06, 9:50AM CST
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) said on Thursday that it has filed a provisional application covering new inventions for its lead compound, AEOL 10150, with the US Patent and Trademark Office.
Aeolus Files Application for New Patent on AEOL 10150
Marketwire - Thu Dec 05, 10:15AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
Marketwire - Tue Sep 17, 12:30PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
Marketwire - Wed Sep 11, 11:21AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Aeolus Pharmaceuticals Inc falls to net loss of USD786,000 in Q3 fiscal 2013
M2 - Thu Aug 15, 10:07AM CDT
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) announced on Wednesday a net loss of USD786,000 (USD0.01 per share) for the three months ended 30 June 2013.
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
Marketwire - Wed Aug 14, 3:30PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months and nine months ended June 30, 2013.
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
Marketwire - Tue Jul 02, 7:00AM CDT
Aeolus Pharmaceuticals (OTCQB: AOLS)
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
Marketwire - Wed Jun 26, 1:03PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
Marketwire - Fri May 17, 1:20PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds to protect against radiological and chemical threats and for use in oncology, announced the appointment of John M. Clerici, Mitchell D. Kaye, and Jeffrey A. Scott, M.D., to its board of directors and accepted the resignations of Joseph J. Krivulka, Michael E. Lewis, PhD, and Peter D. Suzdak, PhD.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Malignant Mesothelioma Therapeutics Pipeline Review 2014 - Analysis of 13 Companies & 22 Drug Profiles
M2 - Tue Apr 22, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db52sm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - MedImmune, LLC - Aduro BioTech, Inc. - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Advantagene, Inc. - Y's Therapeutics Co., Ltd. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - AEOL-10150 - Ad5-SGE-REIC/Dkk3 Gene Therapy - BAY-949343 - BERTA - BIW-8962 - BNC-105 - Bivalent Bispecific Tribody - CRS-207 - Drug For Mesothelioma - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - FPI-01 - LY-3023414 - Monovalent Trispecific Tribody - Oshadi D - Oshadi D Oshadi R - SentoClone - VS-4718 - YP-223 - YP-3 - YS-110 - YYP-218 - tremelimumab For more information visit http://www.researchandmarkets.com/research/db52sm/malignant
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
Marketwire - Fri Feb 14, 4:30PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2013.
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
Marketwire - Thu Feb 13, 6:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
Marketwire - Mon Feb 10, 6:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure
M2 - Fri Jan 24, 5:42AM CST
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) revealed on Thursday the receipt of notice for AEOL 10150 for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
Marketwire - Thu Jan 23, 9:53AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
Aeolus Announces Fiscal Year 2013 Financial Results
Marketwire - Mon Dec 23, 7:00AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months and twelve months ended September 30, 2013.
Aeolus Pharmaceuticals Inc submits application for new patent for AEOL 10150 for use in radiation exposure
M2 - Fri Dec 06, 9:50AM CST
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) said on Thursday that it has filed a provisional application covering new inventions for its lead compound, AEOL 10150, with the US Patent and Trademark Office.
Aeolus Files Application for New Patent on AEOL 10150
Marketwire - Thu Dec 05, 10:15AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
Marketwire - Tue Sep 17, 12:30PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
Marketwire - Wed Sep 11, 11:21AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Aeolus Pharmaceuticals Inc falls to net loss of USD786,000 in Q3 fiscal 2013
M2 - Thu Aug 15, 10:07AM CDT
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) announced on Wednesday a net loss of USD786,000 (USD0.01 per share) for the three months ended 30 June 2013.
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
Marketwire - Wed Aug 14, 3:30PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months and nine months ended June 30, 2013.
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
Marketwire - Tue Jul 02, 7:00AM CDT
Aeolus Pharmaceuticals (OTCQB: AOLS)
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
Marketwire - Wed Jun 26, 1:03PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
Marketwire - Fri May 17, 1:20PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds to protect against radiological and chemical threats and for use in oncology, announced the appointment of John M. Clerici, Mitchell D. Kaye, and Jeffrey A. Scott, M.D., to its board of directors and accepted the resignations of Joseph J. Krivulka, Michael E. Lewis, PhD, and Peter D. Suzdak, PhD.
